Market Place
Sourcing Support
Treadwell Announces Ocifisertib has Received Orphan Designation
20 Feb 2024 //
BUSINESSWIRE
Treadwell Announces the Formation and Members of Scientific Advisory Board
13 Feb 2024 //
BUSINESSWIRE
Treadwell Therapeutics Announces a Presentation at the 2023 ASH Annual Meeting
15 Dec 2023 //
GLOBENEWSWIRE
Treadwell Announces Strategic Pipeline Prioritization and Leadership Transitions
06 Dec 2023 //
GLOBENEWSWIRE
Treadwell Announces the Appointment of Roger Sidhu as Chief Medical Officer
03 Feb 2023 //
PR NEWSWIRE
Treadwell Announces Fast Track Designation Granted by the FDA to CFI-402257
10 Jan 2023 //
PR NEWSWIRE
Treadwell Announces Presentation at ASH Featuring Trial Update on CFI-400945
13 Dec 2022 //
PRNEWSWIRE
Treadwell Announces Presentation Featuring Trial Update on CFI-402257
09 Dec 2022 //
BIONJ
Treadwell begins subject dosing in Phase Ib/II cancer therapy trial
14 Jun 2022 //
CLINICALTRIALSARENA
Treadwell Announces FTD Granted by the FDA to CFI-400945 for AML
26 Apr 2022 //
PRNEWSWIRE
Treadwell Therapeutics Announces US FDA Clearance of INDfor Phase 2 CFI-402257
30 Nov 2021 //
PRNEWSWIRE
Treadwell Closes $91 Million Series B Financing
18 Nov 2021 //
PRNEWSWIRE
Treadwell Therapeutics Announces a Presentation at the 2021 SITC
12 Nov 2021 //
BUSINESSWIRE
Treadwell Therapeutics Announces Acquisition of TCRyption
15 Oct 2021 //
BUSINESSWIRE
Treadwell Announces Initiation of Patient Dosing in TWT-202, a Phase 1b/2
29 Apr 2021 //
BUSINESSWIRE
Treadwell Announces Two Presentations at the 2020 ASH Annual Meeting TriaL
07 Dec 2020 //
BUSINESSWIRE
Treadwell Announces Two Presentations at the 2020 ASH Annual Meeting Featuring
07 Dec 2020 //
BUSINESSWIRE
Treadwell Announces Initiation of New Clinical Trial of CFI-400945
20 Oct 2020 //
YAHOO
Treadwell Announces Initiation of Patient Dosing who have Solid Tumors
02 Sep 2020 //
BUSINESSWIRE
Treadwell Announces Initiation of Expansion PH1 Study of Oral TTK, CFI-402257
27 Aug 2020 //
BUSINESSWIRE
Treadwell Announces Initiation of Expansion Cohorts Ongoing Ph1 StudyCFI-402257
27 Aug 2020 //
BUSINESSWIRE
Treadwell Announces Initiation of Phase 2 Study of CFI-400945 and Durvalumab
12 Aug 2020 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.